Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn

Table of Contents

December 01, 1996; Volume 50,Issue 6
  • You have access
    Overlapping drug interaction sites of human butyrylcholinesterase dissected by site-directed mutagenesis.
    Y Loewenstein-Lichtenstein, D Glick, N Gluzman, M Sternfeld, H Zakut and H Soreq
    Molecular Pharmacology December 1996, 50 (6) 1423-1431;
  • You have access
    Analysis of the alpha2C-adrenergic receptor gene promoter and its cell-type-specific activity.
    J S Saulnier-Blache, Q Yang, J D Sherlock and S M Lanier
    Molecular Pharmacology December 1996, 50 (6) 1432-1442;
  • You have access
    Activation of the skeletal muscle ryanodine receptor by suramin and suramin analogs.
    M Hohenegger, M Matyash, K Poussu, A Herrmann-Frank, S Sarközi, F Lehmann-Horn and M Freissmuth
    Molecular Pharmacology December 1996, 50 (6) 1443-1453;
  • You have access
    Basis for the loss of aryl hydrocarbon receptor gene expression in clones of a mouse hepatoma cell line.
    J Zhang, A J Watson, M R Probst, E Minehart and O Hankinson
    Molecular Pharmacology December 1996, 50 (6) 1454-1462;
  • You have access
    Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIalpha (p170) and IIbeta (p180).
    M Cornarotti, S Tinelli, E Willmore, F Zunino, L M Fisher, C A Austin and G Capranico
    Molecular Pharmacology December 1996, 50 (6) 1463-1471;
  • You have access
    Acquired camptothecin resistance of human breast cancer MCF-7/C4 cells with normal topoisomerase I and elevated DNA repair.
    A Fujimori, M Gupta, Y Hoki and Y Pommier
    Molecular Pharmacology December 1996, 50 (6) 1472-1478;
  • You have access
    Inverse agonist-induced up-regulation of the human beta2-adrenoceptor in transfected neuroblastoma X glioma hybrid cells.
    D J MacEwan and G Milligan
    Molecular Pharmacology December 1996, 50 (6) 1479-1486;
  • You have access
    Enhanced biological activity of antisense oligonucleotides complexed with glycosylated poly-L-lysine.
    A J Stewart, C Pichon, L Meunier, P Midoux, M Monsigny and A C Roche
    Molecular Pharmacology December 1996, 50 (6) 1487-1494;
  • You have access
    Inhibition of capacitative Ca2+ entry into cells by farnesylcysteine analogs.
    Y Xu, B A Gilbert, R R Rando, L Chen and A H Tashjian
    Molecular Pharmacology December 1996, 50 (6) 1495-1501;
  • You have access
    Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells.
    T Cihlar and M S Chen
    Molecular Pharmacology December 1996, 50 (6) 1502-1510;
  • You have access
    Transgenic mice with high levels of superoxide dismutase activity are protected from the neurotoxic effects of 2'-NH2-MPTP on serotonergic and noradrenergic nerve terminals.
    A M Andrews, B Ladenheim, C J Epstein, J L Cadet and D L Murphy
    Molecular Pharmacology December 1996, 50 (6) 1511-1519;
  • You have access
    Effects of volatile anesthetics on the G protein-regulated muscarinic potassium channel.
    J Magyar and G Szabo
    Molecular Pharmacology December 1996, 50 (6) 1520-1528;
  • You have access
    Transport of adenosine by recombinant purine- and pyrimidine-selective sodium/nucleoside cotransporters from rat jejunum expressed in Xenopus laevis oocytes.
    S Y Yao, A M Ng, M W Ritzel, W P Gati, C E Cass and J D Young
    Molecular Pharmacology December 1996, 50 (6) 1529-1535;
  • You have access
    Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance.
    P A Vasey, N A Jones, S Jenkins, C Dive and R Brown
    Molecular Pharmacology December 1996, 50 (6) 1536-1540;
  • You have access
    Subtype-selective inhibition of N-methyl-D-aspartate receptors by haloperidol.
    V I Ilyin, E R Whittemore, J Guastella, E Weber and R M Woodward
    Molecular Pharmacology December 1996, 50 (6) 1541-1550;
  • You have access
    4-Aminoquinoline resistance of Plasmodium falciparum: insights from the study of amodiaquine uptake.
    P G Bray, S R Hawley and S A Ward
    Molecular Pharmacology December 1996, 50 (6) 1551-1558;
  • You have access
    Physicochemical properties correlated with drug resistance and the reversal of drug resistance in Plasmodium falciparum.
    P G Bray, S R Hawley, M Mungthin and S A Ward
    Molecular Pharmacology December 1996, 50 (6) 1559-1566;
  • You have access
    Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan.
    J E Leysen, W Gommeren, L Heylen, W H Luyten, I Van de Weyer, P Vanhoenacker, G Haegeman, A Schotte, P Van Gompel, R Wouters and A S Lesage
    Molecular Pharmacology December 1996, 50 (6) 1567-1580;
  • You have access
    Enantioselectivity of steroid-induced gamma-aminobutyric acidA receptor modulation and anesthesia.
    L L Wittmer, Y Hu, M Kalkbrenner, A S Evers, C F Zorumski and D F Covey
    Molecular Pharmacology December 1996, 50 (6) 1581-1586;
  • You have access
    Reconstitution of recombinant bovine A1 adenosine receptors in Sf9 cell membranes with recombinant G proteins of defined composition.
    R A Figler, S G Graber, M A Lindorfer, H Yasuda, J Linden and J C Garrison
    Molecular Pharmacology December 1996, 50 (6) 1587-1595;
  • You have access
    Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: evidence for multiple receptor states.
    J Van Rampelbergh, P Gourlet, P De Neef, P Robberecht and M Waelbroeck
    Molecular Pharmacology December 1996, 50 (6) 1596-1604;
  • You have access
    Relative contribution of polar interactions and conformational compatibility to the binding of neurokinin-1 receptor antagonists.
    T M Fong, H Yu, R R Huang, M A Cascieri and C J Swain
    Molecular Pharmacology December 1996, 50 (6) 1605-1611;
  • You have access
    Acid-catalyzed oxidation of the anticancer agent mitoxantrone by nitrite ions.
    K J Reszka and C F Chignell
    Molecular Pharmacology December 1996, 50 (6) 1612-1618;
  • You have access
    The third extracellular loop of the human delta-opioid receptor determines the selectivity of delta-opioid agonists.
    E V Varga, X Li, D Stropova, T Zalewska, R S Landsman, R J Knapp, E Malatynska, K Kawai, A Mizusura, H Nagase, S N Calderon, K Rice, V J Hruby, W R Roeske and H I Yamamura
    Molecular Pharmacology December 1996, 50 (6) 1619-1624;
  • You have access
    Evidence for an internal phenylalkylamine action on the voltage-gated potassium channel Kv1.3.
    H Rauer and S Grissmer
    Molecular Pharmacology December 1996, 50 (6) 1625-1634;
  • You have access
    Site-directed mutagenesis of the human A1 adenosine receptor: influences of acidic and hydroxy residues in the first four transmembrane domains on ligand binding.
    H Barbhaiya, R McClain, A Ijzerman and S A Rivkees
    Molecular Pharmacology December 1996, 50 (6) 1635-1642;
  • You have access
    The role of inactivation in open-channel block of the sodium channel: studies with inactivation-deficient mutant channels.
    A O Grant, J E John, V V Nesterenko, C F Starmer and J R Moorman
    Molecular Pharmacology December 1996, 50 (6) 1643-1650;
  • You have access
    Inverse agonistic effect of ICI-174,864 on the cloned delta-opioid receptor: role of G protein and adenylyl cyclase activation.
    T T Chiu, L Y Yung and Y H Wong
    Molecular Pharmacology December 1996, 50 (6) 1651-1657;
  • You have access
    Identification and pharmacological characterization of [125I]L-750,667, a novel radioligand for the dopamine D4 receptor.
    S Patel, S Patel, R Marwood, F Emms, D Marston, P D Leeson, N R Curtis, J J Kulagowski and S B Freedman
    Molecular Pharmacology December 1996, 50 (6) 1658-1664;
  • You have access
    Evans blue antagonizes both alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate and kainate receptors and modulates receptor desensitization.
    C J Price and L A Raymond
    Molecular Pharmacology December 1996, 50 (6) 1665-1671;
  • You have access
    Novel nonpeptide agents potently block the C-type inactivated conformation of Kv1.3 and suppress T cell activation.
    A Nguyen, J C Kath, D C Hanson, M S Biggers, P C Canniff, C B Donovan, R J Mather, M J Bruns, H Rauer, J Aiyar, A Lepple-Wienhues, G A Gutman, S Grissmer, M D Cahalan and K G Chandy
    Molecular Pharmacology December 1996, 50 (6) 1672-1679;
  • You have access
    Calcium-dependent inactivation of recombinant N-methyl-D-aspartate receptors is NR2 subunit specific.
    J J Krupp, B Vissel, S F Heinemann and G L Westbrook
    Molecular Pharmacology December 1996, 50 (6) 1680-1688;
Back to top
PreviousNext

In this issue

Molecular Pharmacology
Vol. 50, Issue 6
1 Dec 1996
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts
  • Most Cited
  • Most Read
Loading
  • SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7
  • The G-Protein-Coupled Receptors in the Human Genome Form Five Main Families. Phylogenetic Analysis, Paralogon Groups, and Fingerprints
  • Pharmacological Properties of Y-27632, a Specific Inhibitor of Rho-Associated Kinases
  • Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
  • The Orphan Human Pregnane X Receptor Mediates the Transcriptional Activation of CYP3A4 by Rifampicin through a Distal Enhancer Module
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics